Methotrexat Ebewe (Methotrexate Disodium)

Methotrexate blocks the enzyme dihydrofolate reductase, which is required to regenerate tetrahydrofolate, a co‑factor for synthesising purine and pyrimidine nucleotides. This interruption reduces DNA, RNA and protein synthesis, especially in rapidly dividing cells such as activated lymphocytes and malignant hematopoietic cells, providing both immunosuppressive and antineoplastic effects.

The dose of Methotrexat Ebewe is individualized by the prescribing clinician based on the specific indication, disease severity, patient weight, renal function, and response to therapy. Dosage regimens can differ markedly between rheumatoid arthritis, oncology protocols, and other uses, so the exact amount and frequency are set by the treating physician.

Methotrexat Ebewe is classified as pregnancy category X because it is known to cause fetal malformations and embryotoxicity. It must not be used by pregnant women, and effective contraception is required during treatment and for a defined period after the last dose. Breastfeeding is also contraindicated, as methotrexate can be excreted in milk and harm the infant.

To request Methotrexat Ebewe, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and the necessary import documentation.

Methotrexat Ebewe (methotrexate) shares a similar mechanism with other antimetabolites such as pemetrexed and pralatrexate, but it is distinguished by its broad therapeutic range—from autoimmune diseases to multiple cancers—and its long history of clinical use. Compared with newer agents, methotrexate is generally less expensive but may require more intensive monitoring for toxicity.

Methotrexat Ebewe should be stored at controlled room temperature, typically below 25 °C, in its original packaging. The container should be kept tightly closed, protected from light, and stored away from moisture. Do not freeze the product, and avoid exposing it to extreme temperatures that could compromise stability.

Methotrexat Ebewe is supplied as a sterile solution for injection and can be given by intramuscular, intravenous, or subcutaneous routes, depending on the clinical indication and physician preference. Administration is performed by a qualified healthcare professional, with dosing intervals and infusion rates determined by the treating clinician.

The most serious adverse events include bone‑marrow suppression leading to pancytopenia, severe hepatotoxicity or hepatic fibrosis, pulmonary toxicity such as interstitial pneumonitis, life‑threatening infections due to immunosuppression, and rare but severe cutaneous reactions like Stevens‑Johnson syndrome. Prompt monitoring and early detection are essential to mitigate these risks.

Methotrexat Ebewe is contraindicated in pregnant women, individuals with known hypersensitivity to methotrexate or its excipients, patients with severe renal or hepatic impairment, and those with active, uncontrolled infections. Caution is also advised for patients with pre‑existing blood dyscrasias or pulmonary disease, and it should be avoided in combination with certain interacting medications.